Thrombolytic Science, LLC (TSI) is a private, clinical stage biopharmaceutical company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots.[1] Gurewich co-founded the company and the founding CEO is business person Alexis Wallace.[2]
TSI's lead drug candidate is a synergistic sequential dual therapy combination of mutant prourokinase (the precursor form of urokinase) and a small dose of tPA [Tissue Plasminogen Activator]. TSI is developing its dual therapy as a potential treatment for conditions caused by blood clots, initially for ischemic stroke[2][3] and heart attacks.
The company completed a Phase I trial in The Netherlands in 2017.
The company raised $8 million by 2012 mostly from an undisclosed angel investor.[1][2]
Referencesedit
^ abWeintraub, Arlene (31 July 2012). "TSI Preps for Trials of New Clot-Busting Drug". Xconomy.
^ abcRhodes, Jennifer (6 February 2012). "Specifying Stroke" (PDF). BioCentury.
^"TS 01". AdisInsight. Retrieved 22 February 2018.
External linksedit
TSI website
May 11, 2024
thrombolytic, science, international, thrombolytic, science, private, clinical, stage, biopharmaceutical, company, that, founded, 2006, based, research, harvard, scientist, victor, gurewich, into, potential, prourokinase, break, blood, clots, gurewich, founded. Thrombolytic Science LLC TSI is a private clinical stage biopharmaceutical company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots 1 Gurewich co founded the company and the founding CEO is business person Alexis Wallace 2 Thrombolytic Science LLC TSI Company typePrivateIndustryBiotechnologyHeadquartersCambridge MAWebsitetsillc net TSI s lead drug candidate is a synergistic sequential dual therapy combination of mutant prourokinase the precursor form of urokinase and a small dose of tPA Tissue Plasminogen Activator TSI is developing its dual therapy as a potential treatment for conditions caused by blood clots initially for ischemic stroke 2 3 and heart attacks The company completed a Phase I trial in The Netherlands in 2017 The company raised 8 million by 2012 mostly from an undisclosed angel investor 1 2 References edit a b Weintraub Arlene 31 July 2012 TSI Preps for Trials of New Clot Busting Drug Xconomy a b c Rhodes Jennifer 6 February 2012 Specifying Stroke PDF BioCentury TS 01 AdisInsight Retrieved 22 February 2018 External links editTSI website Retrieved from https en wikipedia org w index php title Thrombolytic Science International amp oldid 997888376, wikipedia, wiki, book, books, library,
